PMC:6218602 / 7622-8333 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/6218602","sourcedb":"PMC","sourceid":"6218602","source_url":"https://www.ncbi.nlm.nih.gov/pmc/6218602","text":"Traditionally, for those patients who are unable to obtain adequate positive symptom control or sustain a response with at least 2 dopamine receptor-2 (D2)-blocking agents at therapeutic doses for at least 6 weeks, clozapine is the recommended drug of choice. An estimated 30–60% of these patients will respond to clozapine and have what can be described as a clozapine-responsive psychosis (10, 15, 16). Patients who do not have an optimal response to clozapine and continue to experience prominent positive symptoms have clozapine-resistant psychosis or an ultra-resistant psychotic disease (11). Currently, there are no therapies that address this most severe form of neural-dysconnectivity in schizophrenia.","tracks":[{"project":"2_test","denotations":[{"id":"30425662-3046553-41865333","span":{"begin":392,"end":394},"obj":"3046553"},{"id":"30425662-7977880-41865334","span":{"begin":396,"end":398},"obj":"7977880"},{"id":"30425662-9524789-41865335","span":{"begin":400,"end":402},"obj":"9524789"},{"id":"30425662-16518132-41865336","span":{"begin":594,"end":596},"obj":"16518132"}],"attributes":[{"subj":"30425662-3046553-41865333","pred":"source","obj":"2_test"},{"subj":"30425662-7977880-41865334","pred":"source","obj":"2_test"},{"subj":"30425662-9524789-41865335","pred":"source","obj":"2_test"},{"subj":"30425662-16518132-41865336","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"2_test","color":"#ec93e0","default":true}]}]}}